Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma
Go back to Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma| Agilent Technologies Inc (NYSE: A) | Delayed: 139.74 +6.28 (4.71%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $133.46 | 52 Week High | $48.63 | |||
| Open | $139.26 | 52 Week Low | $34.15 | |||
| Day High | $141.95 | P/E | 64.69 | |||
| Day Low | $137.52 | EPS | $2.16 | |||
| Volume | 2,935,855 | |||||
